Actively Recruiting
Marshall Vein Ethanol Infusion in Addition to Pulsed Electric Field Ablation Versus Pulsed Electric Field Ablation Alone for Paroxysmal Atrial Fibrillation
Led by Beijing Anzhen Hospital · Updated on 2025-08-07
340
Participants Needed
1
Research Sites
108 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The Marvel-PAF trial is an investigator initiated, multi-center, open-label, randomized trial, which aims to compare the effectiveness of vein of Marshall in addition to pulmonary vein isolation using pulsed field ablation in the treatment of paroxysmal atrial fibrillation. The primary endpoint is any atrial arrhythmias lasting ≥30s without AAD during 12 months after procedure excluding the 2-months blanking period.
CONDITIONS
Official Title
Marshall Vein Ethanol Infusion in Addition to Pulsed Electric Field Ablation Versus Pulsed Electric Field Ablation Alone for Paroxysmal Atrial Fibrillation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 18 years
- Symptomatic paroxysmal atrial fibrillation
- Undergoing first atrial fibrillation ablation
- At least one atrial fibrillation episode lasting over 30 seconds documented by ECG, Holter, or rhythm monitor in the past 12 months
- Able to understand study purpose, willing to be randomized, and able to attend follow-ups with signed informed consent
You will not qualify if you...
- Persistent atrial fibrillation lasting more than 7 days
- Blood clots in the heart
- Contraindications to oral anticoagulants including history of heparin-induced thrombocytopenia
- Atrial fibrillation caused by electrolyte imbalance, thyroid disease, or other non-cardiac causes
- Acute coronary syndrome within past 3 months or recent coronary intervention
- Stroke or transient ischemic attack within past 3 months
- History of cardiac surgery involving the left atrium
- Severe valvular disease or certain heart muscle diseases
- Left atrium diameter over 55mm by recent TEE exam
- Other conditions unsuitable for surgery such as recent organ transplant, life expectancy under 1 year, uncontrolled cancer, pregnancy, breastfeeding, or planning pregnancy
- Any other reasons deemed unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Anzhen Hospital Affiliated to Capital Medical University
Beijing, Beijing Municipality, China, 100029
Actively Recruiting
Research Team
C
Caihua Sang, MD
CONTACT
Y
Yiwei Lai
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here